Effects of COVID-19 on cardiovascular system

doi:10.3969/j.issn.1006-7795.2020.04.028

Abstract

Abstract: In addition to typical respiratory system symptoms, some patients with COVID-19 have a clinical presentation of cardiovascular impairment. Such patients are more likely to progress to severe illness or death. However, the pathological mechanism of COVID-19 is not yet fully understood, and the changes of cardiovascular system need further analysis and research. Based on the existing literature, this paper preliminarily reviewed the possible damage mechanism of cardiovascular system, including the direct damage of myocardial cells and conduction system by virus, the damage of cardiovascular system by complications or accompanying conditions such as hypoxemia, inflammatory response, stress, and the influence of drugs.

Key words: COVID-19, cardiovascular system, multiple organ failure

CLC Number:

R563.1

Yang Yi, Lu Xuran, Liu Nan, Hou Xiaotong, Sun Lizhong, Wu Long, Pan Youmin, Wang Shoufeng, Zhao Xinyan. Effects of COVID-19 on cardiovascular system[J]. Journal of Capital Medical University, 2020, 41(4): 657-663.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.04.028

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I4/657

References 26

[1]	World Health Organization. WHO issues consensus document on the epidemiology of SARS. (2003-10-17). https://www.who.int/csr/sars/archive/epiconsensus/en/.
[2]	国家卫生健康委办公厅. 新型冠状病毒感染的肺炎诊疗方案(试行第六版). (2020-02-21).http://www.nhc.gov.cn/yzygj/s7652m/202002/54e1ad5c2aac45c19eb541799bf637e9.shtml.
[3]	Australian Government Department of Health. Middle East Respiratory Syndrome Coronavirus (MERS-CoV)[J]. Krankenhaus-Hygiene Infektionsverhütung,2013,36(1):34-35.
[4]	World Health Organization. WHO MERS global summary and assessment of risk,July.2019.(2019-07).https://apps.who.int/iris/handle/10665/326126.
[5]	国家卫生健康委员会.国家卫生健康委员会新闻发布会.(2020-02-04). http://www.nhc.gov.cn/xwzb/webcontroller.do?titleSeq=11220&gecstype=1.
[6]	Huang C L, Wang Y M,Li X W, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet, 2020,395:497-506.
[7]	胡盛寿,杨跃进,朱曼璐,等.心脑血管基础疾病对严重急性呼吸综合征病情和发生多器官功能障碍综合征的影响[J].中华医学杂志,2004,84(15):1257-1259.
[8]	中国疾病预防控制中心COVID-19应急响应机制流行病学组.COVID-19流行病学特征分析[J].中华流行病学杂志,2020,41(2):145-151.
[9]	周光德,赵景民,王松山,等.SARS冠状病毒对心脏及其传导系统影响的病理学研究[J]. 解放军医学杂志,2004,2(1):52-54.
[10]	Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus[J]. Ann Saudi Med,2016,36(1):78-80.
[11]	Li W, Moore M J, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature (London),2003,426(6965):450-454.
[12]	高珺, 刘必成. 血管紧张素转化酶2——肾素-血管紧张素系统重要的负调节剂[J]. 肾脏病与透析肾移植杂志,2007,16(4):360-363.
[13]	Oudit G Y, Kassiri Z, Jiang C,et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS[J]. Eur J Clin Investigat,2009,39(7):618-625.
[14]	Ge X Y, Li J L, Yang X L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor[J].Nature,2013,503(7477):535-538.
[15]	Xu X, Chen P, Wang J,et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sc China Life Sc,2020,63(3):457-460
[16]	Nanshan C, Min Z, Xuan D, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study[J]. Lancet,2020,395:507-513.
[17]	Guan W J, Ni Z Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Eng J Med, 2020, 382(18).
[18]	Wong C K, Lam C W K, Wu A K L, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J]. Clin Exp Immunol, 2004,136(1):95-103.
[19]	Mahallawi W H, Khabour O F, Zhang Q, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile[J]. Cytokine, 2018,104:8-13.
[20]	Cassavaugh J, Lounsbury K M. Hypoxia-mediated biological control[J]. J Cell Biochem,2011,112(3):735-744.
[21]	Liu P P, Mason J W. Advances in the understanding of myocarditis[J]. Circulation,2001,104(9):1076-1082.
[22]	Pudil R, Pidrman V, Krejsek J, et al. The effect of trimetazidine on C-reactive protein, cytokines and adhesion molecules in the course of acute myocardial infarction[J]. Acta Med,2001,44(4):135-140.
[23]	Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock[J]. Crit Care Med,2008,36(6):1701-1706.
[24]	Chu, M C. Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax,2004,59(3):252-256.
[25]	李红芳,邓勇志.高血压患者感染新型冠状病毒:原用ACEI或ARB是否应继续使用?[J].临床心血管病杂志,2020,36(3):204-208.
[26]	ESH.ESH Statement on COVID-19:Statement of the European Society of Hypertension (ESH) on hypertension,Renin Angiotensin System blockers and COVID-19. (2020-4-15). https://www.eshonline.org/esh-content/uploads/2020/06/Statement-ESH-on-Hypertension-RAS-Blockers-and-COVID-19-Update-April-15-2020.pdf.